18 Oct Exact Sciences Strengthens Pipeline Capabilities With Acquisition Of Biomatrica, A Leading Provider Of Biological Sample Preservation Technology
MADISON, Wis. and SAN DIEGO, Oct. 18, 2018 /PRNewswire/ — Exact Sciences Corp. (Nasdaq: EXAS) today announced the acquisition of Biomatrica, a leading developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry. Biomatrica’s sample collection tubes, which contain proprietary, sample-stabilizing chemistry, ensure quality preservation of circulating tumor DNA, cells and other biomarkers in biological specimens throughout shipment and storage. Exact Sciences intends to use Biomatrica’s proprietary technology to support ongoing and future development of its own blood-based cancer detection tests.
“To detect cancer at its earliest stages, you need the right team backed by the highest-quality science, data and materials,” said Kevin Conroy, chairman and CEO of Exact Sciences. “Biomatrica’s preservation chemistry ensures the reliability of results, even when blood and other biological samples undergo the stresses of shipping and storage.”
Established in 2005, Biomatrica holds eight issued United States utility patents, one issued U.S. design patent, and 36 issued patents in foreign jurisdictions. Four additional patents are pending in the U.S. These patents pertain to technologies that stabilize biological materials. Under the terms of the acquisition, Biomatrica will operate as a wholly owned subsidiary of Exact Sciences and will continue to supply tubes and sample preservation technologies to other companies.
Sorry, the comment form is closed at this time.